Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
95% Confidence Interval
7%
Advanced Hepatocellular Carcinoma
25%
Adverse Events
5%
Atezolizumab
16%
Bevacizumab
9%
Cirrhosis
6%
Growth Factors
6%
Hazard Ratio
5%
Hepatitis C Virus
6%
Hepatocellular Carcinoma
100%
Hepatocellular Carcinoma Patient
11%
Immune Checkpoint Inhibitors
15%
Insulin-like
7%
Intrahepatic Cholangiocarcinoma (iCCA)
5%
Liver
5%
Liver Transplantation
5%
Median Overall Survival
5%
Neoadjuvant Therapy
5%
Nivolumab
6%
Overall Survival
25%
Partial Response
5%
Phase I Trial
6%
Progression-free Survival
12%
Sorafenib
17%
Systemic Therapy
9%
Thymoquinone
6%
Tumor
6%
Unresectable Hepatocellular Carcinoma (uHCC)
13%
Medicine and Dentistry
Atezolizumab
6%
Bevacizumab
6%
Cancer
5%
Cholangiocarcinoma
12%
Diseases
13%
Genetics
6%
Hepatocellular Carcinoma
88%
Immune Checkpoint Inhibitor
10%
Immunotherapy
9%
Liver Cancer
5%
Liver Cirrhosis
5%
Liver Transplantation
7%
Malignant Neoplasm
12%
Neoadjuvant Therapy
5%
Neoplasm
13%
Overall Survival
23%
Progression Free Survival
9%
Radiation Therapy
7%
Somatomedin C
6%
Sorafenib
11%
Systemic Therapy
8%
Transcatheter Arterial Chemoembolization
5%
Tumor
5%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
8%
Atezolizumab
10%
Bevacizumab
11%
Diseases
6%
Immune Checkpoint Inhibitor
6%
Immunotherapy
7%
Liver Cell Carcinoma
56%
Malignant Neoplasm
11%
Neoplasm
6%
Overall Survival
10%
Progression Free Survival
7%
Sorafenib
13%
Thymoquinone
5%